Analyst Research Report Snapshot

Title:

Obagi Medical Products, Inc.

Price:

$50.00

Provider:

MarketLine (a Datamonitor Company)

Date:

23 Jan 2013

Pages:

29

Type:

AcrobatPDF

Companies referenced:

OMPI.OQ

Available for Immediate Download
Summary:

Obagi Medical Products, Inc. - Company Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, product and service offerings, and corporate actions, providing a 360° view of the company. Features: - Detailed information on Obagi Medical Products, Inc. required for business and competitor intelligence needs - Intelligence on Obagi Medical Products, Inc.’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors - News about Obagi Medical Products, Inc., such as business expansion, restructuring, and contract wins - Large number of easy-to-grasp charts and graphs that present important data and key trends Highlights: Obagi Medical Products, Inc. Company Profile is the essential source for top-level company data and information. Obagi Medical Products, Inc. Company Profile examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy. Obagi Medical Products is a pharmaceutical company that develops, markets and sells, proprietary topical aesthetic and therapeutic prescription-strength skin care systems in the physician-dispensed market. The company’s products are used to improve penetration of agents across the skin barrier for common and visible skin conditions in adult skin including premature aging, photodamage, hyperpigmentation (irregular or patchy discoloration of the skin), acne, sun damage, rosacea, and soft tissue deficits, such as fine lines and wrinkles. The company’s portfolio includes cosmetic, over-the-counter and prescription products. The company primarily operates in the US, where it is headquartered in Long Beach, California and employs around 199 people. The company recorded revenues of $114.1 million in the fiscal year ended December 2011, an increase of 1.2% over 2010. The company's operating profit was $16 million in fiscal 2011, an increase of 1.2% over 2010. Its net profit was $10 million in fiscal 2011, an increase of 5.6% over 2010. Scope of the Report - Provides all the crucial information on Obagi Medical Products, Inc. required for business and competitor intelligence needs -Data is supplemented with details on Obagi Medical Products, Inc. history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available statement from Obagi Medical Products, Inc. Reasons to Purchase - Support sales activities by understanding your customers’ businesses better - Understand prospective partners and suppliers - Keep fully up to date on your competitors’ business structure, strategy and prospects - Obtain the most up to date company information available Reasons to Purchase: - Gain understanding of Obagi Medical Products, Inc. the company and its strategies - Track strategic initiatives of the company and latest corporate news and actions - Assess Obagi Medical Products, Inc. as a prospective partner, vendor or supplier - Support sales activities by understanding your customers' businesses better - Stay up to date on Obagi Medical Products, Inc. your competitors' business structure, strategy and prospects

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.